| abstract |
The present invention provides a family of antibodies that specifically bind human epithelial cell adhesion molecules. These antibodies contain modified variable regions, more particularly modified framework regions, that reduce their immunogenicity upon administration to humans. These antibodies, when linked to the appropriate moiety, can be used for cancer diagnosis, prognosis and treatment. |